MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS, INC. ADVIA CENTAUR XP HBSAGII CONFIRMATORY (CONF); HEPATITI B CONFIRMATORY IMMUNOASSAY

Model Number N/A

Device Problems False Negative Result (1225); No Apparent Adverse Event (3189)

Patient Problem No Known Impact Or Consequence To Patient (2692)

Event Date 03/03/2020

Event Type  malfunction  

Manufacturer Narrative

Siemens healthcare diagnostics is investigating.There is no sample that can be sent to siemens for evaluation.The customer was not able to provide the patient's medical status or a list of medications/supplements the patient is taking.Siemens reviewed the calibration provided and there is no evidence of a problem.The customer did not provide control data.The percent agreement section of the advia centaur xp/xpt (b)(6) instructions for use (ifu) (10635153 revision h, 2019-07) lists the 95% confidence interval (ci) for negative agreement as 99.5% - 100% so a certain number of(b)(6) results can be expected for this assay.The percent agreement section of the advia centaur xp/xpt (b)(6) instructions for use (ifu) (10635153 revision h, 2019-07) lists the 95% confidence interval (ci) for(b)(6) agreement as 92.0% - 98.8% so a certain number of(b)(6) results can be expected for this assay.The discrepant samples from this one patient do not indicate a product problem with advia centaur xp (b)(6).A review of siemens' internal data indicates advia centaur xp (b)(6) lots 188 and 204 are performing as intended.Based on the investigation to date, the cause of the discrepant results seen by the customer with samples from this one patient when using advia centaur xp (b)(6) could not be determined but siemens cannot rule out pre-analytical factors, a sample issue, or normal assay performance; no product problem was identified to date.Siemens has requested instrument service information.The advia centaur xp/xpt (b)(6) confirmatory instructions for use (ifu) under the results section states the following: "the system reports advia centaur (b)(6) confirmatory results as invalid, redilute, not confirmed, or confirmed: samples are reported as invalid if the sample run with reagent b is below the cutoff value of the advia centaur(b)(6) confirmatory assay.The assay is invalid and should be repeated.If the interpretation is invalid after repeat testing, it means a valid result cannot be obtained with this sample and a new sample should be obtained." mdr 1219913-2020-00096 was filed for the 03/03/2020 discordant (b)(6) results.Mdr 1219913-2020-00098 was filed for the 02/25/2020 discordant(b)(6) result.

Event Description

A customer obtained an erroneous result of "not confirmed" using advia centaur xp (b)(6) confirmatory assay compared to previous results on the same day and a different day.The customer indicates that the patient is considered (b)(6) for (b)(6) infection.The erroneous result of "not confirmed" was not reported to physician.Patient treatment was not prescribed or altered.There was no report of adverse health consequences due to the false negative (b)(6) results.

Manufacturer Narrative

Siemens filed initial mdr 1219913-2020-00097 on 03/10/2020.Additional information from 05/05/2020: service was not dispatched for this notification as the issue was related to one sample and no system deficiencies were suspected.No further sample issues reported; no system issue identified.Additional information from 05/08/2020: the customer was not able to provide the patient's medical status or a list of medications/supplements the patient is taking.The sample was not able to be provided for futher investiggation.Siemens reviewed the calibration provided and there is no evidence of a problem.The customer did not provide control data.A review of internal data indicates advia centaur xp/xpt hbsii lots 188 and 204 are performing as intended.The cause of the discrepant results seen by the customer with samples from this one patient when using advia centaur xp hbsii lots 188 and 204 and the advia centaur xp hbsag conf assay could not be determined but siemens cannot rule out pre-analytical factors, a sample issue, or normal assay performance.Based on the investigation, no product problem was identified.The result code and conclusion code have been updated to reflect the addtional information.Reference section h6 of this report for the updated codes.Mdr 1219913-2020-00096 supplemental report 1 was filed for the 03/03/2020 discordant hbsagii results.Mdr 1219913-2020-00098 supplemental report 1 was filed for the 02/25/2020 discordant hbsagii result.

Manufacturer Narrative

Siemens filed initial mdr 1219913-2020-00097, on (b)(6) 2020, and mdr 1219913-2020-00097, supplemental report 1 on (b)(6) 2020.Additional information from (b)(6) 2020: technical application service (tas) assistance was requested by customer for potential software issue because the sample initially resulted as reactive, but was automatically repeated by the system which resulted as non-reactive.The non-reactive result was sent to laboratory information system.Additional information from (b)(6) 2020: siemens investigation is complete.Siemens reviewed the instrument and event data including any actions performed by the customer service engineer (cse).No cse service was dispatched for this notification.The issue regarding the false positive patient result was found to be related to one patient sample.Siemens concluded that the cause of the discordant result was due to pre-analytical factors or a sample issue.No system hardware troubleshooting by field service was required, and the customer was satisfied.Regarding the issue present in the ticket of multiple replicates being run, the technical application service (tas) team member reviewed the system software settings for the advia centaur xpt and centralink.The tas observed that the final result rule, above check range, and above linearity settings were all selected, which cause the advia centaur xpt to run replicates.The tas removed the selections in order to stop repeats from being ordered from the advia centaur xpt instrument itself in addition to what was being ordered by centralink middleware.This allowed only centralink middleware to order replicates for reactive specimens.Post-tas support, the customer reports the system is handling hbsagii repeat testing correctly and there is no further concern.The system is now operational and fully functional.Based on the investigation, no assay or system or software problems were identified.No further investigation is required.Mdr 1219913-2020-00096, supplemental report 2 was filed for the (b)(6) 2020, discordant hbsagii result.Mdr 1219913-2020-00098, supplemental report 2 was filed for the (b)(6) 2020, discordant hbsagii result.

• Brand Name: ADVIA CENTAUR XP HBSAGII CONFIRMATORY (CONF)
• Type of Device: HEPATITI B CONFIRMATORY IMMUNOASSAY
• Manufacturer (Section D): SIEMENS HEALTHCARE DIAGNOSTICS, INC.; 511 benedict avenue; tarrytown, ny
• MDR Report Key: 9950992
• MDR Text Key: 240417659
• Report Number: 1219913-2020-00097
• Device Sequence Number: 1
• Product Code: LOM
• UDI-Device Identifier: 00630414472874
• UDI-Public: 00630414472874
• Combination Product (y/n): N
• PMA/PMN Number: P030049
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: health professional,user faci
• Type of Report: Initial,Followup,Followup
• Report Date: 07/14/2020

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Date FDA Received: 04/10/2020
• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Device Operator: Health Professional
• Device Model Number: N/A
• Device Catalogue Number: 10309058
• Device Lot Number: UNKNOWN
• Was Device Available for Evaluation?: No
• Date Manufacturer Received: 06/15/2020
• Is This a Reprocessed and Reused Single-Use Device?: No
• Patient Sequence Number: 1